
REVANESSE®
ULTRA™+

Instructions for Use

SYMBOL:



Syringe fluid path sterilized using moist heat



Sterilized by irradiation



SYRINGE



NEEDLE



Read the instructions before using the product



Do not use if the package has been damaged



Do not reuse



Keep away from sunlight



Keep dry



Store between 2 and 25 °C



Expiration date



Lot number





Manufacturer



Date of Manufacture



EU Importer



ASSEMBLY OF NEEDLE TO SYRINGE:

1. Remove needle guard cap and unscrew the glass syringe end cap.
2. Firmly grip the glass syringe Luer-lock with thumb and forefinger.
3. Align the needle to the glass syringe Luer-lock.
4. Hold the glass syringe still and rotate the needle until it is tightly affixed.
5. Immediately prior to injection, remove needle guard by pulling forward (do not rotate).

COMPOSITION

Cross-linked hyaluronic acid.....	25mg/ml
Lidocaine.....	3mg/ml (0.3% w/w)
In phosphate buffered saline	
[Cross-linked with Butanediol-diglycidylether (BDD)]	

DESCRIPTION

Revesense® Ultra™ is a colorless, odorless, transparent and aqueous gel of synthetic origin. The gel is stored in a pre-filled disposable syringe. Each box contains two 1.0 or 1.2ml syringes of Revesense® Ultra™ along with up to two sterilized needles.

APPLICATION RANGE / INDICATIONS

Application: Moderate to severe facial wrinkles and folds.

Medical Indications: The products are space-occupying tissue reconstructive materials composed of a hyaluronic acid gel that is indicated for restoration of volume lost from lipatrophy/lipodystrophy, and/or correction of contour deficiencies and anatomic deformities of either pathologic origin or after trauma, in facial soft tissue, such as HIV-associated lipatrophy and lipodystrophy.

Intended patients are those desiring the treatment of contour deficiencies and deformities in facial soft tissue, such as HIV-associated lipatrophy and lipodystrophy.

Cosmetic Indication: Revesense® Ultra™ is indicated for the treatment of facial rhytides, volume restoration, lip augmentation, skin hydration and contouring of depressions by injection into tissue.

ANTICIPATED SIDE EFFECTS

Physicians must inform patients that with every injection of Revesense® Ultra™ there are potential adverse reactions that may be delayed or occur immediately after the injection. These include but are not limited to:

- Injection-related reactions might occur, such as transient erythema, swelling, pain, itching, discoloration or tenderness at the injection site. These reactions may last for one week.
- Nodules or induration are also possible at the injection site.
- Poor product performance due to improper injection technique.
- Glabella necrosis, abscess formation, granulomas, hypersensitivity, nasolacrimal duct obstruction and alopecia have all been reported with injections of hyaluronic acid products. It is important for physicians to take these reactions into account on a case-by-case basis.

Reactions thought to be of hypersensitivity in nature have been reported in less than one in every 1500 treatments. These have consisted of prolonged erythema, swelling and induration at the implant site.

These reactions have started either shortly after injection or after a delay of 2 – 4 weeks and have been described as mild or moderate, with an average duration of 2 weeks. Typically, this reaction is self-limiting and resolves spontaneously with time. However, it is imperative that patients with hypersensitivity type reactions contact their physician immediately for assessment. Patients with multiple allergic reactions should be excluded from the treatment.

CONTRAINDICATIONS

- Products are contraindicated in cases of hypersensitivity to all local amide-type anesthetics (not only to lidocaine as indicated in the package leaflet), as well as to all degrees of retrobulbar block, sinus node dysfunction, severe decline in myocardial contractility, porphyria, supraventricular tachycardias.
- Contains lidocaine and is contraindicated for patients with a history of allergies to such material.
- Do not inject Revesense® Ultra™ into eye contours (into the eye circle or eyelids).
- Pregnant women, or women during lactation should not be treated with Revesense® Ultra™+.
- Revesense® Ultra™+ is only intended for intradermal use and must not be injected into blood vessels. This may occlude and could cause an embolism.
- Patients who develop hypertrophic scarring should not be treated with Revesense® Ultra™+.
- Contains trace amounts of gram-positive bacterial proteins and is contraindicated for patients with a history of allergies to such material.
- Never use Revesense® Ultra™+ in conjunction with a laser, intense pulsed light, chemical peeling or dermabrasion treatments.
- People under the age of 18 should not be treated with Revesense® Ultra™+.
- Patients with acne and/or other inflammatory diseases of the skin should not be treated with Revesense® Ultra™+.
- Patients with unattainable expectations.
- Patients with auto-immune disorders or under immunotherapy.
- Patients with multiple severe allergies.
- Patients with acute or chronic skin disease in or near the injection sites.
- Coagulation defects or under anti-coagulation therapy.
- Patients with sensitivity to hyaluronic acid.

It is imperative that patients with adverse inflammatory reactions that persist for more than one week report this immediately to their physician. These conditions should be treated as appropriate (i.e. corticosteroids or antibiotics). All other types of adverse reactions should be reported directly to the authorized distributor of the Revesense® family of products and / or to ProLience Medical Technologies Inc. directly.

ADMINISTRATION & DOSAGE

- Revesense® Ultra™ should only be injected by or under the direct supervision of qualified physicians who have been trained on the proper injection technique for filling facial wrinkles.
- Before patients are treated, they should be informed of the indications of the device as well as its contraindications and potential undesirable side effects.
- The area to be treated must be thoroughly disinfected. Be sure to inject only under sterile conditions.
- Inject the product slowly and apply the least amount of pressure necessary.
- Revesense® Ultra™+ and needles packaged with it are for single use only. Do not re-use. If re-used, there is a risk of infection or transmission of blood-borne diseases.
- Keep the product at room temperature for 30 minutes prior to injection.
- If the skin turns a white color (blanching), the injection should be stopped immediately, and the area should be massaged until the skin returns to its normal color.
- Before injecting, press on the plunger of the syringe until a small drop is visible at the tip of the needle.

PRECAUTIONS

- If intravascular injections are made by mistake, the toxic effect will be noticed within 1-3 minutes (so the doctor and the patient should be alert in case of error).
- The effect of lidocaine may be reduced if infusion occurs in an inflammation or infection area.
- Special attention should be given to patients with partial or complete retrobulbar block because local anesthetics may suppress myocardial conduction in patients with advanced liver disease or severe renal impairment, in patients with asthma, in patients with respiratory failure, in the elderly age, in patients with poor general health status, in patients receiving class III antiarrhythmics (eg amiodarone), who must be under close medical supervision including electrocardiogram due to the possible addition of cardiac effects, and finally in patients with acute porphyria.
- Lidocaine should be used with caution in patients receiving other topical anesthetics or agents with structural similarities to local amide-type anesthetics, e.g. certain antiarrhythmics, such as mexiletine and tocainide, since systemic toxic effects can be cumulative.
- In addition to the direct anesthetic effect, local anesthetics may exert a very mild effect on the cognitive function and movement coordination and may temporarily affect smooth motility and alertness. Depending on the dose, local anesthetics may have a very minor effect on mental function and may temporarily disturb movement and movement coordination.
- Revesense® Ultra™+ should not be injected into an area that already contains another filler product as there is no available clinical data on possible reactions.
- Revesense® Ultra™+ should not be injected into an area where there is a permanent filler or implant.
- Hyaluronic acid products have a known incompatibility with quaternary ammonium salts such as benzalkonium chloride. Please ensure that Revesense® Ultra™+ never comes into contact with this substance or medical instrument that has come into contact with this substance.
- Revesense® Ultra™+ should never be used for breast enlargement, or for implantation into bone, tendon, ligament or muscle.
- Avoid touching the treated area for 12 hours after injection and avoid prolonged exposure to sunlight, UV, as well as extreme cold and heat.
- Until the initial swelling and redness have resolved, do not expose the treated area to intense heat (e.g. solarium and sunbathing) or extreme cold.
- If you have previously suffered from facial cold sores, there is a risk that the needle punctures could contribute to another eruption of cold sores.
- If you are using aspirin, non-steroidal anti-inflammatory medications, St. John's Wort or High doses of Vitamin E supplements prior to treatment or any similar medications be aware that these may increase bruising and bleeding at the injection site.
- Based on a toxicological risk assessment for lidocaine, patients should be limited to 20 ml per 60 kg (130 lbs) body mass per annum. The safety of injecting greater amounts has not been established.
- The safety for use in patients under 18 years or over 65 years has not been established.
- Patients who are visibly ill, with bacterial or viral infections, influenza, or active fever should not be treated until a resolution of their symptoms.
- In order to minimize the risks of potential complications, this product should only be used by health care practitioners who have appropriate training, experience, and who are knowledgeable about the anatomy at and around the site of injection.
- Health care practitioners are encouraged to discuss all potential risks of soft tissue injection with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

WARNINGS

- Confirm that the seal on the box has not been broken and sterility has not been compromised. Confirm that the product has not expired. Product is for single use only; do not re-use. If re-used, there is a risk of infection or transmission of blood-borne diseases.
- Introduction of product into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction.
- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, and damage to underlying facial structures.
- Immediately stop the injection if a patient exhibit any of the following symptoms, including changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure.
- Patients should receive prompt medical attention and possibly evaluation by an appropriate health care practitioner specialist should an intravascular injection occur.

The Revesense® family of products should not be used in areas that have high vascularity. Use in these areas such as the glabella and nose region has resulted in cases of vascular embolization and symptoms consistent with ocular vessel occlusion (i.e.: blindness).

SHELF LIFE & STORAGE

- Expiry is indicated on each individual package. Store between 2°-25° C, and protect from direct sun light and freezing.
- NOTE:** The correct injection technique is crucial to treatment success & patient satisfaction. Revesense® Ultra™+ should only be injected by a practitioner qualified according to local laws and standards.
- The graduation on the syringe is not precise and should be used as a guide only. The amount of material to be injected is best determined by visual and tactile assessment by the user.

DISPOSAL

After use, syringes and needles should be handled as potential biohazards. Disposal should be in accordance with accepted medical practice and applicable local, state and national regulations.

PROLIENCE MANUFACTURER

ProLience Medical Technologies, Inc.
138 Industrial Parkway North, Aurora, ON
L4G 4C3, Canada

Australian Sponsor:
Taevas Life Sciences Pty Ltd,
46 Dora St, Blacktown,
NSW 2148, Australia



Emergo Europe B.V.
Westervoortsedijk 60
6827 AT Arnhem
The Netherlands



MedEnvoy Global B.V.
Prinses Margrietplantsoen
33-Suite 123
2595 AM The Hague
The Netherlands

PROLLENIUM[®]
MEDICAL TECHNOLOGIES INC

T: +1.866.353.3015 | T: +1.905.508.1469
E: info@prollenium.com | www.prollenium.com